What’s New in CLL Therapies at ASH 2024
January 24, 2025
Dr. Nicole Lamanna discusses upcoming novel therapies for CLL / SLL from the American Society for Hematology (ASH) annual meeting, a scientific conference.
Dr. Nicole Lamanna discusses upcoming novel therapies for CLL / SLL from the American Society for Hematology (ASH) annual meeting, a scientific conference.
January 2025 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
New novel agents are being tested in clinical trials to help patients with CLL who have developed resistance to all the BTK inhibitors and BCL2 inhibitors.
December 2024 CLL Bloodline – Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
The goal of the CLL Treatment Decision Tool is to increase your understanding of your chronic lymphocytic leukemia (CLL) and your treatment options.
CLL patient Mark Silverstein passed away after his cancer turned to Richter’s transformation. His widow shared his unfinished reflection on his diagnosis.
Epcoritamab, a bispecific antibody, shows encouraging early results in relapsed / refractory chronic lymphocytic leukemia (CLL) patients.
A variety of tests are used to capture images inside the body when chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are present.
Resistance mutations in BTK and PLCG2 are common in patients with CLL who progress on acalabrutinib, a BTK inhibitor treatment that is taken continuously.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911